Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880449 | 0.83 | MAPT (0.35) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL23705155 | 0.78 | POLB (0.35) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL27180317 | 0.76 | FOLH1 (0.35) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL26902931 | 0.74 | KMT2A (0.37) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL29868004 | 0.74 | KMT2A (0.37) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL29867983 | 0.74 | KMT2A (0.37) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL27179563 | 0.74 | KMT2A (0.37) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL23705112 | 0.74 | KMT2A (0.37) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL26902904 | 0.74 | FOLH1 (0.40) | FOLH1DGAT1KDM4EMAPTALDH1A1 | |
| SCHEMBL27180315 | 0.74 | FOLH1 (0.35) | FOLH1DGAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | FOLH1 661/4885DGAT1 1879/4885KDM4E 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.